TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35729519
Drug: Ethinyl Estradiol
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl Estradiol (EE) therapy
Study: 35248120
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS combined with conventional rehabilitation therapy
Study: 35248120
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS combined with conventional rehabilitation treatment
Study: 33277455
Drug: L-Carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Carnitine (2 g/d orally)
Study: 35236065
Drug: Health resort
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health resort treatment (HRT) without iodine-bromine baths (IB)
Study: 35236065
Drug: Health resort
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health resort treatment (HRT) with iodine-bromine baths (IB)
Study: 33608793
Drug: Pulse intravenous
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse intravenous (IV) methylprednisolone (MEP) defined as ≥ 200 mg
Study: 35708633
Drug: Methylsulfonylmethane (MSM)
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylsulfonylmethane (MSM) treatment
Study: 35708633
Drug: Sesame seed
Normalized name: SESAME SEED
DrugBank: Sesame seed (DB10566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sesame seed oil (SSO) treatment
Study: 35708633
Drug: MSM+SSO combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSM+SSO combination treatment
Study: 35708633
Drug: Diabetic control,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic control, no treatment
Study: 35708633
Drug: All T2D
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All T2D treatment groups
Study: 32252976
Drug: Tanezumab 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 2.5 mg and Tanezumab 2.5/5 mg
Study: 35705450
Drug: Opioid-free pathway
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free pathway (100 mg gabapentin TID, 15 mg ketorolac Q6 hours, 1 mg scheduled IV acetaminophen Q6 hours)
Study: 35705450
Drug: Opioid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid treatment (tramadol, hydrocodone-acetaminophen, or oxycodone-acetaminophen)
Study: 32618252
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) and focal MDA (fMDA)
Study: 33191772
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (1.8 g daily)
Study: 36075387
Drug: IPCA hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPCA hydromorphone with bolus‐only dose (A1)
Study: 36075387
Drug: IPCA hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPCA hydromorphone with continuous infusion (A2)
Study: 36075387
Drug: Oral extended‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended‐release morphine (B)
Study: 35228117
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus standardised medical care (CBT+SMC)
Study: 32513290
Drug: Therapeutic plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic plasma exchange (TPE) administered using the Spectra Optia TM Apheresis System, first dose of 1.5 plasma volumes followed by one plasma volume on alternate days or daily for five to seven total treatments.
Study: 32513290
Drug: Usual empiric
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual empiric treatment for COVID-19 without TPE.
Study: 35022874
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (40 mg of triamcinolone acetate solution applied to carpal tunnel)
Study: 35022874
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) (applied five times a week for a total of 15 sessions, fluence of 6 j/cm2 for 1 min per point at a wavelength of 830 nm)
Study: 35022874
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection and LLLT
Study: 34562208
Drug: AlphaWave® l-Theanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AlphaWave® l-Theanine (200 mg)
Study: 34302449
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg TERN-101 capsules
Study: 34302449
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg TERN-101 capsules
Study: 34302449
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg TERN-101 capsules
Study: 34302449
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg TERN-101 tablets
Study: 34302449
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg TERN-101 tablets
Study: 32461104
Drug: Durvalumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab treatment arm
Study: 35356991
Drug: Low‐irradiance photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment (18.5 mW/cm2)
Study: 35356991
Drug: Conventional photodynamic
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photodynamic therapy (61.67 mW/cm2)
Study: 35356991
Drug: Low‐irradiance photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐irradiance photodynamic therapy combined with Er:YAG pretreatment
Study: 34247932
Drug: Intrathecal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of recombinant human heparan-N-sulfatase (rhHNS) 45 mg
Study: 33486526
Drug: JUUL System
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL System 59 mg/mL
Study: 33486526
Drug: JUUL System
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL System 18 mg/mL
Study: 33486526
Drug: JUUL System
Approvals — FDA: no, EMA: no, PMDA: no
Description: JUUL System 9 mg/mL
Study: 32359666
Drug: Clinician-administered SBIRT
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-administered SBIRT
Study: 32297783
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg lisdexamfetamine dimesylate
Study: 33775153
Drug: In-person prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person prolonged exposure therapy
Study: 33775153
Drug: Telemedicine prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine prolonged exposure therapy
Study: 33775153
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment conditions (in-person and telemedicine)
Study: 34256133
Drug: Diet 2
Normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 2 (40 g kg−1 WMRP)
Study: 34256133
Drug: Diet 3
Normalized name: Phendiet 35 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 3 (108 CFU g−1 LP)
Study: 34256133
Drug: Diet 4
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet 4 (40 g kg−1 WMRP + 108 CFU g−1 LP)
Study: 34256133
Drug: Control (Diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Diet 1: 0 g kg−1 WMRP and 0 CFU g−1 L. plantarum)
Study: 34432975
Drug: RTS,S/AS01E (vaccine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E (vaccine)
Study: 34432975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RTS,S/AS01E and chemoprevention
Study: 34432975
Drug: Combination vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vs Chemoprevention
Study: 34432975
Drug: Combination vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vs Vaccine
Study: 33553973
Drug: Capsule FMT
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule FMT
Study: 33553973
Drug: Antibiotics+enema FMT
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics+enema FMT
Study: 32967513
Drug: Personalized psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized psychological interventions, routine nursing care and drug treatment
Study: 32967513
Drug: Routine nursing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine nursing care and drug treatment
Study: 35263346
Drug: 10 minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 minute therapy dog team visit in addition to usual care
Study: 35263346
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no therapy dog visit)
Study: 36241842
Drug: Blended chemotherapy
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended chemotherapy (including FP, carboplatin plus paclitaxel, FOLFOX, FOLFIRI, docetaxel plus FP, trastuzumab plus FP, and trastuzumab plus FOLFOX)
Study: 34418716
Drug: Bilateral vapocoolant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral vapocoolant spray
Study: 34418716
Drug: Unilateral vapocoolant
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral vapocoolant spray
Study: 33460301
Drug: Ibudilast treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast treatment
Study: 35349397
Drug: Balanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution (Plasma‐Lyte 148)
Study: 35436797
Drug: Selective, clopidogrel-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective, clopidogrel-based therapy (unguided de-escalation)
Study: 35436797
Drug: Selective, clopidogrel-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective, clopidogrel-based therapy (guided clopidogrel therapy)
Study: 35436797
Drug: Selective, clopidogrel-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective, clopidogrel-based therapy (overall)
Study: 35436797
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (ticagrelor or prasugrel)
Study: 32285142
Drug: Levofloxacin +
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin + dexamethasone sodium phosphate (L-DSP) eye drops
Study: 32285142
Drug: Levofloxacin (L)
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin (L) eye drops
Study: 34404384
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 mcg/kg intravenous
Study: 34404384
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 mcg/kg intravenous
Study: 34195809
Drug: Rule-out profile
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rule-out profile based on the 0/1-h high-sensitivity cardiac troponin T protocol (<5 ng/L or ≤12 ng/L and a change of <3 ng/L at 1-h)
Study: 33362221
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements with 50% milk protein
Study: 33362221
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements with 20% milk protein in CSB
Study: 33362221
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) vs Corn-soy blends (CSB)
Study: 36008814
Drug: Pegloticase +
Normalized name: Pegloticase
DrugBank: Pegloticase (DB09208)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegloticase + methotrexate (15 mg/week) and folic acid (1 mg/day) administered 4 weeks before and during pegloticase therapy.
Study: 35848358
Drug: Standard (ST)
Normalized name: ST-36
DrugBank: ST-36 (DB17275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard (ST) preoperative chemotherapy
Study: 35848358
Drug: Histotype-tailored (HT)
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histotype-tailored (HT) preoperative chemotherapy
Study: 35848358
Drug: Standard (S)
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard (S) chemotherapy
Study: 35848358
Drug: Histotype-tailored (HT)
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histotype-tailored (HT) chemotherapy
Study: 34449183
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K Antagonists
Study: 33719265
Drug: 120 mmHg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mmHg (group L)
Study: 33252985
Drug: BGF 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 320 (320/18/9.6 μg)
Study: 33252985
Drug: BGF 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGF 160 (160/18/9.6 μg)
Study: 33252985
Drug: GFF (18/9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF (18/9.6 μg)
Study: 33252985
Drug: BFF (320/9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFF (320/9.6 μg)
Study: 35050796
Drug: Apnea training
Normalized name: SLEEP APNEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apnea training (5 maximal static apneas daily for 6 weeks)
Study: 33745107
Drug: Deferred therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred therapy (control)
Study: 33651027
Drug: Effervescent tablet
Normalized name: Pain Relief Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablet (ET)
Study: 33651027
Drug: Chitosan solution
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan solution (CH)
Study: 33651027
Drug: Chitosan nanoparticle
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan nanoparticle solution (CN)
Study: 33651027
Drug: Control solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solution (WC)
Study: 35777128
Drug: Relapse Prevention-Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention-Cognitive Behavioral Therapy (CBT-RP)
Study: 32634046
Drug: Best-in-class drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best-in-class drug-eluting stents (DES)
Study: 33809346
Drug: GA with
Normalized name: Tums with Gas Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA with SPI-guided FNT administration
Study: 33809346
Drug: Preventive topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive topical 2% proparacaine (TA)
Study: 33809346
Drug: Preprocedural intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural intravenous infusion of 1.0 g of metamizole (M)
Study: 33809346
Drug: Preprocedural intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural intravenous infusion of 1.0 g of paracetamol (P)
Study: 33573600
Drug: Sequential procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential procedure
Study: 32513312
Drug: Transgenic Camelina
Normalized name: Camelina sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transgenic Camelina sativa seed oil (CSO) 450 mg/d EPA + DHA for 8 weeks
Study: 32513312
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 450 mg/d EPA + DHA for 8 weeks
Study: 35476192
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine surgical treatment)
Study: 35354339
Drug: Emulsion cream
Normalized name: propofol lipid emulsion Injection [Propoven]
DrugBank: Coconut oil (DB14322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulsion cream containing 0.05% APP in triglycerides (APP preparation)
Study: 35354339
Drug: Mineral oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil hydrocarbon (petrolatum)-based skin cream (MHB preparation)
Study: 35354339
Drug: Both APP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both APP and MHB preparations
Study: 32633762
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment in the 30 days before admission
Study: 34274366
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation (MV) on, tidal volume (TV) at 3-4 mL.kg-1 (Group 2)
Study: 34274366
Drug: Mechanical ventilation
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical ventilation (MV) on, tidal volume (TV) at 3-4 mL.kg-1, PEEP at 5 cmH2O (Group 3)
Study: 35512392
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about pharmaceuticals
Study: 35512392
Drug: Perceived sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived sensitivity to medicines
Study: 32297822
Drug: Resin luting
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin luting agent (Nexus 3)
Study: 34516459
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg daily for 3 weeks
Study: 34657193
Drug: Same-day preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day preparation with Sodium Picosulfate/Magnesium Citrate (SPMC)
Study: 34657193
Drug: Split-dose preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose preparation with Sodium Picosulfate/Magnesium Citrate (SPMC)
Study: 33277698
Drug: Mulberry leaf
Normalized name: MULBERRY
DrugBank: Broussonetia papyrifera pollen (DB10736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulberry leaf DNJ (MLD) treatment
Study: 33277698
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (CG)
Study: 32740593
Drug: Closed-incision negative-pressure
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative-pressure therapy malfunction
Study: 32740593
Drug: Closed-incision negative-pressure
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-incision negative-pressure therapy duration longer than 10 days
Study: 32424421
Drug: New biomarkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: New biomarkers for treatment selection
Study: 32424421
Drug: Standard biomarkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard biomarkers for treatment selection
Study: 33691344
Drug: Clarithromycin-based bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin-based bismuth-containing quadruple therapy (C-BQT)
Study: 33691344
Drug: Furazolidone-based bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone-based bismuth-containing quadruple therapy (F-BQT)
Study: 33358848
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) or medication
Study: 34799776
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with 2 J red laser and 3 J infrared laser on 21 points on the tongue
Study: 33506357
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry juice (240 ml)
Study: 33506357
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry powdered capsule (480 mg)
Study: 33506357
Drug: Tart cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart cherry powdered capsule (480 mg, two capsules)
Study: 33140515
Drug: Paclitaxel 80
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 weekly for 12 doses followed by FAC/FEC
Study: 33140515
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m2 on days 1 and 8 of a 21-day cycle for 4 cycles followed by FAC/FEC
Study: 36384081
Drug: Low FODMAP
Normalized name: ProNourish Low FODMAP Enteral Suspension (French Vanilla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low FODMAP diet (4 g/day)
Study: 36384081
Drug: Moderate FODMAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate FODMAP diet (23 g/day)
Study: 33504175
Drug: Cognitive Therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy for Grief
Study: 32553279
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) group, 80 kV with a NI of 25 and iohexol (350 mg I/ml)
Study: 32553279
Drug: Further Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further Low Dose (FLD) group, 80 kV with a NI of 30 and iomeprol (400 mg I/ml)
Study: 32553279
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (LD) group
Study: 32553279
Drug: Further Low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further Low Dose (FLD) group
Study: 32553279
Drug: Conventional Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Dose (CD) group, 100 kV with a NI of 25 and iohexol (350 mg I/ml)
Study: 35894487
Drug: Oral NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NSAIDs with 60 minutes wait
Study: 36408023
Drug: Sugemalimab plus
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab plus chemotherapy (SC)
Study: 36408023
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus chemotherapy (PC)